Shuang S Liu, 633304 Jasper St, West Lafayette, IN 47906

6403054, Jun 11, 2002

May 28, 1997

08/864586

Shuang Liu - Chelmsford MA, 01823

Bristol-Myers Squibb Pharma Company - Princeton NJ

A61K 5104

424 165, 424 177, 534 10, 534 14

The present invention provides novel radiopharmaceuticals useful for imaging the heart, brain, lungs, liver or kidneys, kits useful for preparing the radiopharmaceuticals, and methods of imaging the heart, brain, lungs, liver or kidneys in a patient in need of such imaging. The radiopharmaceuticals are comprised of technetium or rhenium radionuclide complexes of a ternary ligand system: one hydrazido or diazenido ligand, one aminoalcohol ligand, and one pi-acid ligand selected from phosphines, arsines, and imine nitrogen-containing heterocycles. The radiopharmaceuticals have the formula, ML L L , wherein the variables are as defined herein.

6416733, Jul 9, 2002

Oct 3, 1997

08/943659

John A. Barrett - Groton MA
Edward H. Cheesman - Lunenburg MA
Thomas D. Harris - Salem NH
Shuang Liu - Chelmsford MA
Milind Rajopadhye - Westford MA
Michael Sworin - Tyngsboro MA

Bristol-Myers Squibb Pharma Company - Princeton NJ

A61K 5100

424 165, 424 169, 534 10

The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

6565828, May 20, 2003

Apr 5, 2001

09/826549

Shuang Liu - Chelmsford MA

Bristol-Myers Squibb Company - Princeton NJ

A61K 5100

424 153, 424 111, 424 91, 424 165, 534 10, 534 14, 534 15

This invention relates to new macrocyclic chelants and metal chelates thereof, methods of preparing the chelants and metal chelates, and pharmaceutical compositions comprising the macrocyclic chelants and metal chelates. This invention relates particularly to the use of the new metal chelates as contrast agents in X-ray or CT, MRI imaging, and radiopharmaceuticals for the diagnosis of cardiovascular disorders, infectious disease and cancer. This invention also relates to new bifunctional chelants (BFCs) for attaching diagnostic metals and therapeutic isotopes to target-specific biomolecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands. In addition, the macrocyclic chelants are useful for heavy metal detoxification.

6517814, Feb 11, 2003

Dec 27, 2001

10/033765

Shuang Liu - Chelmsford MA

Bristol-Myers Squibb Pharma Company - Princeton NJ

A61B 5055

424 936, 424 111, 424 165, 424 91, 424 93, 424 9362, 424 94, 424 9361, 534 10, 534 14

Macrocyclic chelant are disclosed, as well as chelates of the chelants with metal ions to form radiopharmaceutical and radioactive, MRI and X-ray or CT imaging compounds and compositions. Therapeutic and imaging methods of use are also disclosed.

6534038, Mar 18, 2003

Apr 5, 2001

09/826449

Shuang Liu - Chelmsford MA

Bristol-Myers Squibb Pharma Company - Princeton NJ

A61K 4900

424 91, 424 111, 424 165, 424 173, 534 14, 568 17

This invention relates to novel highly functionalized phosphine ligands as ancillary ligands in radiopharmaceuticals. Also, this invention provides radiopharmaceuticals comprised of highly functionalized phosphine ligated Tc labeled HYNIC-conjugated biomolecules that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy. The invention also provides methods of use of the radiopharmaceuticals as imaging agents for the diagnosis of cardiovascular disorders such as thromboembolic disease or atherosclerosis, infectious disease and cancer.

6537520, Mar 25, 2003

Jun 21, 2000

09/599295

Milind Rajopadhye - Westford MA
D. Scott Edwards - Burlington MA
John A. Barrett - Groton MA
Thomas D. Harris - Samel NH
Stuart J. Heminway - Lowell MA
Shuang Liu - Chelmsford MA
Prahlad R. Singh - Arlington MA

Bristol-Myers Squibb Pharma Company - Princeton NJ

A61K 5100

424 169, 424 111, 424 165, 424 91, 534 14

The present invention describes novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

6685914, Feb 3, 2004

Sep 12, 2000

09/660377

Shuang Liu - Chelmsford MA

Bristol-Myers Squibb Pharma Company - Princeton NJ

A61B 4900

424 93, 424 111, 424 91, 424 165, 540465, 534 10, 534 14

This invention relates to macrocyclic chelants comprised of one or two heteroatom-containing bridges, compositions containing them and their use in medicine, particularly in diagnostic imaging and radiotherapy. This invention relates especially to the use of metal chelates of the macrocyclic chelants as metallopharmaceuticals in Magnetic Resonance Imaging (MRI) and radiopharmaceuticals. This invention also relates to macrocyclic chelants as bifunctional chelating agents (BFCs) for the labeling of biologically active targeting molecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands, with metal ions and radioisotopes.

6713042, Mar 30, 2004

Feb 22, 2002

10/081258

Shuang Liu - Chelmsford MA

Bristol-Myers Squibb Pharma Company - Princeton NJ

A61K 5100

424 165, 424 111, 424 91, 548400, 548401, 549200, 549201

The invention relates to the use of ascorbic acid analogs as buffering reagents and chelating agents for the preparation of metalloradiopharmaceuticals. Also, invention relates to the use of ascorbic acid as a buffering reagent, a chelating agent, and a stabilizer for the preparation and stabilization of radiopharmaceuticals and processes for making and using the same.